RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Regulation Update on Pharmacovigilance and Risk Management in the EU

Regulation Update on Pharmacovigilance and Risk Management in the EU

Posted 01 September 2011 | By

The World Health Organization (WHO) defines "pharmacovigilance" as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.1

Title IX of Directive 2001/83/EC relating to medicinal products for human use (Articles 101 to 108) covers issues related to pharmacovigilance. According to the directive, the objective of a functioning pharmacovigilance system should be to safeguard public health without impeding the free movement of safe medicinal products within the EU.2


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.